View Future GrowthBiotest 과거 순이익 실적현재 이 회사의 최신 실적 보고서를 처리하고 있습니다과거 기준 점검 0/6Biotest은 연평균 47.4%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 17%의 비율로 증가했습니다. 매출은 연평균 10.6%의 비율로 증가했습니다.핵심 정보47.40%순이익 성장률48.62%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률10.55%자기자본이익률-4.81%순이익률-3.86%다음 순이익 업데이트10 Nov 2025최근 과거 실적 업데이트Reported Earnings • May 14First quarter 2025 earnings released: €0.55 loss per share (vs €0.74 profit in 1Q 2024)First quarter 2025 results: €0.55 loss per share (down from €0.74 profit in 1Q 2024). Revenue: €124.2m (down 42% from 1Q 2024). Net loss: €21.4m (down 173% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 01Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: €0.66 (down from €3.21 in FY 2023). Revenue: €726.2m (up 6.1% from FY 2023). Net income: €26.4m (down 79% from FY 2023). Profit margin: 3.6% (down from 19% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.공시 • Mar 18+ 1 more updateBiotest Aktiengesellschaft to Report Q3, 2025 Results on Nov 10, 2025Biotest Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 10, 2025Reported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: €0.25 loss per share. Revenue: €150.7m (down 40% from 3Q 2023). Net loss: €9.30m (down 108% from profit in 3Q 2023). Revenue is forecast to grow 6.0% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.공시 • Nov 15Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025Biotest Aktiengesellschaft announced that they will report fiscal year 2024 results on Mar 28, 2025Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: €0.24 (vs €0.075 loss in 2Q 2023)Second quarter 2024 results: EPS: €0.24 (up from €0.075 loss in 2Q 2023). Revenue: €156.8m (up 20% from 2Q 2023). Net income: €9.70m (up €15.3m from 2Q 2023). Profit margin: 6.2% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Revenue is expected to decline by 6.2% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates공시 • May 23Biotest Aktiengesellschaft announces Annual dividend, payable on July 07, 2025Biotest Aktiengesellschaft announced Annual dividend of EUR 0.0400 per share payable on July 07, 2025, ex-date on July 03, 2025 and record date on July 04, 2025.공시 • May 22Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025, at 10:30 W. Europe Standard Time.Reported Earnings • May 14First quarter 2025 earnings released: €0.55 loss per share (vs €0.74 profit in 1Q 2024)First quarter 2025 results: €0.55 loss per share (down from €0.74 profit in 1Q 2024). Revenue: €124.2m (down 42% from 1Q 2024). Net loss: €21.4m (down 173% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.공시 • Apr 02Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million.Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million on March 31, 2025. The Management Board and the Supervisory Board will carefully review the offer document for the public delisting acquisition offer and issue a joint reasoned statement in accordance with Section 27 of the German Securities Acquisition and Takeover Act. The delisting agreement contains provisions that Grifols, S.A. intends to support Biotest AG in an economically reasonable manner. After the revocation of the stock exchange admission becomes effective, the shares of Biotest AG will no longer be admitted to trading on a domestic regulated market or a comparable market abroad. According to the provisions of the delisting agreement, Grifols Biotest Holdings GmbH, a 100% subsidiary of Grifols, S.A., will make an unconditional public delisting acquisition offer to the shareholders of Biotest AG to acquire all ordinary and preference shares of Biotest AG that are not already held by Grifols Biotest Holdings GmbH, in exchange for a cash consideration of €43.00 per Biotest ordinary share and €30.00 per Biotest preference share, subject to adjustments due to legal provisions. The terms and conditions of the delisting offer will be communicated in the offer document ("Offer Document") to be prepared by Grifols and to be examined by the German federal financial supervisory. Banco Santander, S.A. acted as a financial advisor to Biotest Aktiengesellschaft.Reported Earnings • Apr 01Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: €0.66 (down from €3.21 in FY 2023). Revenue: €726.2m (up 6.1% from FY 2023). Net income: €26.4m (down 79% from FY 2023). Profit margin: 3.6% (down from 19% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.공시 • Mar 18+ 1 more updateBiotest Aktiengesellschaft to Report Q3, 2025 Results on Nov 10, 2025Biotest Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 10, 2025공시 • Mar 07Martin Möller to Leave as Chief Financial Officer of Biotest AG on 15 March 2025The Board of Management of Biotest AG announced that Chief Financial Officer Martin Möller will terminate his position as CFO as planned at the end of his contract expires on 15 March 2025. The Supervisory Board has already initiated the search for a suitable successor and aims to fill the position in the near future. Martin Möller will continue to support Biotest AG in an advisory capacity beyond the end of his contract.공시 • Jan 09Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)Biotest AG announced that the Biologics License Application (BLA) for Biotest’s Fibrinogen has been submitted to the US Food and Drug Administration. Fibrinogen is the second product developed and manufactured by Biotest in Dreieich, Germany, for which a BLA has been submitted to the FDA. The new application covers both supplementation in patients with acquired fibrinogen deficiency and treatment and prophylaxis of acute bleeding episodes in all patients with congenital fibrinogen deficiency. The application is now under evaluation by the FDA, with a decision anticipated by the end of 2025. This submission follows Biotest’s earlier application for marketing authorization in selected European markets filed in October 2024. In many regions of the world, the use of cryoprecipitate or fresh frozen plasma as a fibrinogen substitute is the standard of care for the management of major surgical bleeding. However, these treatments contain not only fibrinogen, but also additional proteins and components that may exhibit undesired effects for the patient. In addition, they are not subject to the same rigorous pathogen safety protocols as Fibrinogen. Fibrinogen also offers the significant advantages of being readily available and allowing for faster administration, ensuring timely and targeted treatment.Reported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: €0.25 loss per share. Revenue: €150.7m (down 40% from 3Q 2023). Net loss: €9.30m (down 108% from profit in 3Q 2023). Revenue is forecast to grow 6.0% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.공시 • Nov 15Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025Biotest Aktiengesellschaft announced that they will report fiscal year 2024 results on Mar 28, 2025Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: €0.24 (vs €0.075 loss in 2Q 2023)Second quarter 2024 results: EPS: €0.24 (up from €0.075 loss in 2Q 2023). Revenue: €156.8m (up 20% from 2Q 2023). Net income: €9.70m (up €15.3m from 2Q 2023). Profit margin: 6.2% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Revenue is expected to decline by 6.2% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.공시 • Jul 29Biotest Aktiengesellschaft to Report Q2, 2024 Results on Aug 06, 2024Biotest Aktiengesellschaft announced that they will report Q2, 2024 results on Aug 06, 2024공시 • Jun 18Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary ImmunodeficienciesGrifols announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration (FDA) for Yimmugo®, an innovative intravenous immunoglobulin (Ig) therapeutic, to treat primary immunodeficiencies (PID). Yimmugo, developed by Biotest, adds to Grifols’ strong franchise of industry-leading intravenous and subcutaneous Ig treatments at a time of growing demand for plasma-derived medicines to treat immunodeficiencies, in which a part of the body’s immune system is missing or does not function properly, and other medical conditions. The first U.S.-approved medicine in Biotest’s portfolio, Yimmugo is produced using a state-of-the-art process at Biotest’s new FDA-certified “Next Level” production facility in Dreieich, Germany, which is already approved for production and marketing in Europe. The launch of Yimmugo in the U.S. in the second part of 2024 follows its successful introduction in Europe at the end of 2022 and is poised to add to Grifols' future revenue growth and profitability. Yimmugo is the first of a threesome of Biotest plasma proteins on the horizon destined for markets including the U.S. The other two, both in late-stage development, are a fibrinogen concentrate (FC) to treat acquired fibrinogen deficiency – it would be the first FC approved for this indication in the U.S. – and trimodulin, a polyvalent Ig to treat community-acquired pneumonia (CAP) or severe community-acquired pneumonia (sCAP). The strategic acquisition of Biotest and the integration of its specialized resources has significantly accelerated Grifols innovation, deepened its product pipeline and furthered its industry leadership. Yimmugo is a newly developed polyvalent immunoglobulin G preparation from human blood plasma for intravenous administration (IVIg). The sugar-free ready-to-use solution is approved in the US for substitution therapy in primary antibody deficiency syndromes. Yimmugo is the first approved product from the new Biotest Next Level production facility. The modern production process stands for the highest product quality and an extremely responsible use of resources. Important Safety Information: Thrombosis may occur with immune globulin intravenous (IGIV) products, including YIMMUGO. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer YIMMUGO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.Reported Earnings • May 07First quarter 2024 earnings released: EPS: €0.74 (vs €0.53 loss in 1Q 2023)First quarter 2024 results: EPS: €0.74 (up from €0.53 loss in 1Q 2023). Revenue: €215.2m (up 84% from 1Q 2023). Net income: €29.5m (up €49.9m from 1Q 2023). Profit margin: 14% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is expected to decline by 4.8% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Upcoming Dividend • May 01Upcoming dividend of €0.08 per shareEligible shareholders must have bought the stock before 08 May 2024. Payment date: 13 May 2024. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.8%).New Risk • Mar 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 53% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.9x net interest cover). Earnings are forecast to decline by an average of 53% per year for the foreseeable future.Reported Earnings • Mar 30Full year 2023 earnings: Revenues exceed analyst expectationsFull year 2023 results: Revenue: €684.6m (up 33% from FY 2022). Net income: €127.0m (up €158.7m from FY 2022). Profit margin: 19% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 21%. Revenue is forecast to grow 2.0% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Germany.공시 • Mar 29Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024, at 10:30 Central European Standard Time. Location: Alte Oper Frankfurt, Mozart Saal, Opernplatz, Franfurt Am Main Germany Agenda: To consider the adopted annual financial statements of Biotest AG and the approved consolidated financial statements as at 31 December 2023; to consider the Resolution on the discharge of the members of the Management Board for the financial year 2023; to consider Resolution on the discharge of the members of the Supervisory Board for the financial year 2023; to consider the Election of the auditor for the financial year 2024; and to consider the other business matters.공시 • Jan 23+ 2 more updatesBiotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024Biotest Aktiengesellschaft announced that they will report first half, 2024 results on Jul 30, 2024공시 • Nov 03Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024Biotest Aktiengesellschaft announced that they will report fiscal year 2023 results on Mar 28, 2024Reported Earnings • Nov 02Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: €252.8m (up 135% from 3Q 2022). Net income: €114.4m (up €128.7m from 3Q 2022). Profit margin: 45% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.공시 • Oct 07Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023Biotest Aktiengesellschaft raised earnings guidance for the year 2023. Biotest AG had forecasted in April 2023 an EBIT that may possibly exceed EUR 100 million. Based on current information, the Executive Board expects EBIT for fiscal 2023 to be in the order of EUR 130 - 170 million. The Executive Board continues to aim for a mid-single-digit percentage increase in revenue for the 2023 financial year compared to 2022, excluding revenue from the technology transfer and licensing agreement.공시 • Oct 06Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024Biotest AG at its meeting held on October 5, 2023 appointed Mr. Peter Janssen (57) as Chairman of the Management Board of Biotest AG with effect from 1 January 2024. He will take over the chairmanship of the Board of Management from Dr Michael Ramroth (62), who held this position for three and a half years and is retiring as planned for reasons of age. Peter Janssen has been a member of the Management Board of Biotest AG since 2022 and heads the Commercial and Industrial Operations divisions. Previously, he was Executive VP of Prothya Netherlands and CEO of Prothya Belgium. Mr. Janssen also worked for Pfizer for 14 years and for its animal health spin-off Zoetis for 5 years. Peter Janssen started his career as an assistant professor at the University of Leuven in Belgium, was a reserve officer in the Belgian Air Force and worked in the semiconductor division of the industrial gas company Air Products in Pennsylvania, USA. He holds a Master of Science (Dipl. Ing.) in Electromechanics, a Master in Business Administration and a Management Diploma from INSEAD in France. In addition to Peter Janssen as Chairman of the Management Board, the Management Board of Biotest AG will continue to include Ainhoa Mendizabal Zubiaga as CFO and Dr. Jörg Schüttrumpf as CSO.New Risk • Sep 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€146m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company.공시 • Sep 13Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with TrimodulinBiotest announced that the first patient with sCAP has been treated in the phase III ESsCAPE trial in an intensive care unit. This multinational phase III clinical trial is expected to enrol approximately 590 adult patients with severe Community Acquired Pneumonia (sCAP). The ESsCAPE trial will be conducted in up to 20 countries worldwide and patients will receive either trimodulin or placebo as add-on therapy to standard of care. Severe CAP is a life-threatening condition. Patients must be admitted to an intensive care unit (ICU) and often receive oxygen through invasive mechanical ventilation (IMV). These patients often develop additional critical illnesses such as sepsis, septic shock, and multiple organ dysfunction or failure. Despite existing treatment options, mortality in these patients remains high. The clinical concept of this prospective, double-blind, placebo-controlled phase III trial, was developed based on the promising results of the previous phase II clinical trial (CIGMA) in 160 sCAP patients requiring IMV. In the CIGMA trial a subgroup of patients with evidence of severe inflammation showed an encouraging reduction in the mortality rate when treated with trimodulin. Biotest's development product trimodulin is a globally unique, innovative polyvalent IgM, IgA, IgG antibody composition, purified from human plasma. In addition to clinical development for sCAP, trimodulin is also currently in development for the treatment of COVID-19. Biotest's development products trimodulin is an innovative polyvalent antibody composition, purified from human Plasma. In comparison to standard IgG preparations (IVIG), trimodulin contains relevant amounts of IgM and IgA in addition to IgG. Trimodulin is currently in clinical development for the treatment of patients with severe community-acquired pneumonia (sCAP) and for patients with moderate or severe COVID-19. Research so far has shown that trimodulin could intervene with a number of mechanisms involved in pathological processes that would otherwise lead to respiratory failure, sepsis, multi-organ failure and finally to death of the patient. Due to the large variety of polyvalent antibodies present in trimodulin, the impaired immune system is supported in various ways. The antibodies bind to various types of pathogens including viruses and bacteria as well as their toxins and support their clearance by the immune system. Particularly the IgM component in trimodulin can reduce dysregulated immune responses, preventing the immune system to attack host tissues, in this case, the lung. In this way, trimodulin may prevent progression of disease, including the need for invasive mechanical ventilation and other intensive care procedures, and finally death. Severe community acquired pneumonia (sCAP) is usually defined as pneumonia acquired outside the hospital that requires intensive medical care. mortality of sCAP patients admitted to the intensive care unit is high and has not improved much in recent years.공시 • Sep 08Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin YimmugoBiotest AG announced that the Biologics License Application (BLA) for the polyspecific immunoglobulin preparation Yimmugo (IgG Next Generation) has been accepted for review by the U.S. Food and Drug Administration (FDA) after the 60-day validation phase. With this filing notification the marketing authorization application will enter the next phase, in which the application dossier will be subjected to an in-depth substantive review. The marketing authorization application covers the indication primary immunodeficiencies (PID). After receiving approval, Biotest plans to expand the indication to include chronic primary immune thrombocytopenia (ITP). The FDA's decision on the marketing authorization application of Yimmugo is expected on June 29, 2024. Biotest's new immunoglobulin is manufactured in an innovative production process and is the main product of the new Biotest Next Level production facility. The new production facility, which uses technologies, represents Biotest's increased commitment to the global immunoglobulin market.Reported Earnings • Aug 13Second quarter 2023 earnings released: EPS: €0.55 (vs €0.39 loss in 2Q 2022)Second quarter 2023 results: EPS: €0.55 (up from €0.39 loss in 2Q 2022). Revenue: €158.0m (up 15% from 2Q 2022). Net income: €22.2m (up €37.2m from 2Q 2022). Profit margin: 14% (up from net loss in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Reported Earnings • May 10First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €117.2m (up 1.1% from 1Q 2022). Net loss: €20.4m (loss widened 316% from 1Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.Reported Earnings • Mar 24Full year 2022 earnings: Revenues miss analyst expectationsFull year 2022 results: Revenue: €516.1m (flat on FY 2021). Net loss: €31.7m (loss narrowed 50% from FY 2021). Revenue missed analyst estimates by 2.2%. Revenue is forecast to grow 9.5% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.Buying Opportunity • Mar 13Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.0%. The fair value is estimated to be €40.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.5% over the last 3 years. Earnings per share has declined by 56%. Revenue is forecast to grow by 21% in 2 years. Earnings is forecast to grow by 86% in the next 2 years.공시 • Feb 11Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023Biotest AG appointed Ms. Ainhoa Mendizabal (50) to the company's Management Board as Chief Financial Officer (CFO) with effect from 15 February 2023. When Dr. Michael Ramroth was appointed Chief Executive Officer (CEO) on 1 May 2019, he initially continued to perform the duties of Chief Financial Officer in addition to his other duties. In view of the constantly growing reporting requirements, the company has now filled the position of Chief Financial Officer with Ms Mendizabal. As 'Chief Financial Officer', Ms. Mendizabal will be responsible within the Biotest Group for the areas of finance, including the treasury and tax departments, controlling, investor relations and insurance. Ms Mendizabal has worked for several years in an international consulting firm in the area of CFO Services and Enterprise Applications. From there she moved to Talecris Biotherapeutics GmbH before Talecris was acquired by Grifols S.A. Since then, Ms Mendizabal has held various executive and managerial roles in the Grifols Group in Germany and in Europe. Ms. Mendizabal holds a dual Master of Business Administration (Business Administration) in Spain and in Germany.공시 • Dec 20+ 2 more updatesBiotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023Biotest Aktiengesellschaft announced that they will report fiscal year 2022 results at 12:00 PM, Central European Standard Time on Mar 23, 2023Reported Earnings • Nov 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €107.7m (down 5.2% from 3Q 2021). Net loss: €14.3m (loss widened 42% from 3Q 2021). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Germany.Breakeven Date Change • Sep 15No longer forecast to breakevenThe 2 analysts covering Biotest no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €9.06m in 2023. New consensus forecast suggests the company will make a loss of €3.00m in 2024.Reported Earnings • Aug 14Second quarter 2022 earnings released: €0.39 loss per share (vs €0.11 loss in 2Q 2021)Second quarter 2022 results: €0.39 loss per share (down from €0.11 loss in 2Q 2021). Revenue: €137.2m (flat on 2Q 2021). Net loss: €15.0m (loss widened 266% from 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.Reported Earnings • May 06First quarter 2022 earnings: Revenues in line with analyst expectationsFirst quarter 2022 results: Revenue: €115.9m (down 3.4% from 1Q 2021). Net loss: €4.90m (loss narrowed 65% from 1Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 2.5%, compared to a 28% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.Upcoming Dividend • Apr 29Upcoming dividend of €0.04 per shareEligible shareholders must have bought the stock before 06 May 2022. Payment date: 10 May 2022. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (4.0%). Lower than average of industry peers (1.4%).Major Estimate Revision • Apr 04Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €0.06 to €0.08. Revenue forecast steady at €559.5m. Net income forecast to grow 60% next year vs 24% growth forecast for Biotechs industry in Germany. Consensus price target of €36.58 unchanged from last update. Share price was steady at €34.70 over the past week.Major Estimate Revision • Dec 11Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -€0.53 to -€1.06 per share. Revenue forecast unchanged at €511.5m. Biotechs industry in Germany expected to see average net income growth of 3.4% next year. Consensus price target broadly unchanged at €39.13. Share price fell 2.8% to €38.10 over the past week.Price Target Changed • Nov 13Price target increased to €38.93Up from €36.23, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of €39.00. The company is forecast to post a net loss per share of €0.54 next year compared to a net loss per share of €0.80 last year.Reported Earnings • Nov 12Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: €113.6m (up 6.4% from 3Q 2020). Net loss: €10.1m (loss narrowed 33% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 13Second quarter 2021 earnings released: €0.11 loss per share (vs €0.16 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses and improved control over expenses, although revenues were flat. Second quarter 2021 results: Revenue: €137.8m (flat on 2Q 2020). Net loss: €4.10m (loss narrowed 29% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance.Reported Earnings • May 12First quarter 2021 earnings released: €0.37 loss per share (vs €0.28 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: €120.0m (up 23% from 1Q 2020). Net loss: €14.1m (loss widened 31% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance.Upcoming Dividend • May 05Upcoming dividend of €0.04 per shareEligible shareholders must have bought the stock before 12 May 2021. Payment date: 17 May 2021. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (0.5%).Reported Earnings • Apr 04Full year 2020 earnings released: €0.80 loss per share (vs €0.13 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €484.2m (up 16% from FY 2019). Net loss: €31.8m (loss widened €26.7m from FY 2019). Products in clinical trials Phase I: 1 Phase II: 1 Phase III: 5 Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.Major Estimate Revision • Apr 02Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from €497.9m to €508.0m. Forecast EPS reduced from -€0.52 to -€0.60 per share. Biotechs industry in Germany expected to see average net income growth of 7.3% next year. Consensus price target up from €31.20 to €35.60. Share price was steady at €29.90 over the past week.Is New 90 Day High Low • Feb 12New 90-day high: €28.80The company is up 10.0% from its price of €26.10 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period.Is New 90 Day High Low • Jan 14New 90-day high: €28.50The company is up 4.0% from its price of €27.40 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also up 4.0% over the same period.Reported Earnings • Nov 13Third quarter 2020 earnings released: €0.39 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: €106.8m (up 7.0% from 3Q 2019). Net loss: €15.1m (loss widened 208% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.Major Estimate Revision • Sep 25Analysts update estimatesThe company's losses in 2020 are expected to worsen with analysts lowering their consensus EPS forecasts from -€0.64 to -€0.72. Revenue estimate was approximately flat at €461.0m. The Biotechs industry in Germany is expected to see an average net income growth of 9.9% next year. The consensus price target increased from €24.10 to €31.20. Share price is down by 2.0% to €24.80 over the past week.매출 및 비용 세부 내역Biotest가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이XTRA:BIO3 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Mar 25635-24815731 Dec 2472626835730 Sep 2470769856830 Jun 24781164876531 Mar 24783177867131 Dec 23685127846730 Sep 2365691845630 Jun 23538-10855731 Mar 23517-47845031 Dec 22516-32825130 Sep 22505-69845130 Jun 22511-65835031 Mar 22512-54825131 Dec 21516-63825230 Sep 21514-28775530 Jun 21507-33785531 Mar 21507-35805631 Dec 20484-31805630 Sep 20466-34825630 Jun 20459-24845431 Mar 20439-15835231 Dec 19419-5835330 Sep 19406-9825230 Jun 19395-3825331 Mar 19390-6825131 Dec 18400-13854930 Sep 1840518915030 Jun 184096915231 Mar 184001995431 Dec 17378-161005530 Sep 17257-48955630 Jun 17301-47935231 Mar 17340-29894931 Dec 164086884830 Sep 16531128783630 Jun 1652552886231 Mar 1652636887231 Dec 1553527937930 Sep 15590-881079330 Jun 1560631097331 Mar 15602161106931 Dec 14582191086730 Sep 145432710572양질의 수익: BIO3 은(는) 현재 수익성이 없습니다.이익 마진 증가: BIO3는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BIO3는 수익성이 없지만 지난 5년 동안 연평균 47.4%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BIO3의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BIO3은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(45%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BIO3는 현재 수익성이 없으므로 자본 수익률이 음수(-4.81%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/09/03 10:30종가2025/06/06 00:00수익2025/03/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biotest GmbH & Co. KGaA는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Torben TeichlerHauck Aufhäuser Investment BankingJan KeppelerHSBCKlaus SchloteSolventis Wertpapierhandelsbank GmbH
Reported Earnings • May 14First quarter 2025 earnings released: €0.55 loss per share (vs €0.74 profit in 1Q 2024)First quarter 2025 results: €0.55 loss per share (down from €0.74 profit in 1Q 2024). Revenue: €124.2m (down 42% from 1Q 2024). Net loss: €21.4m (down 173% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 01Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: €0.66 (down from €3.21 in FY 2023). Revenue: €726.2m (up 6.1% from FY 2023). Net income: €26.4m (down 79% from FY 2023). Profit margin: 3.6% (down from 19% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
공시 • Mar 18+ 1 more updateBiotest Aktiengesellschaft to Report Q3, 2025 Results on Nov 10, 2025Biotest Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 10, 2025
Reported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: €0.25 loss per share. Revenue: €150.7m (down 40% from 3Q 2023). Net loss: €9.30m (down 108% from profit in 3Q 2023). Revenue is forecast to grow 6.0% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
공시 • Nov 15Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025Biotest Aktiengesellschaft announced that they will report fiscal year 2024 results on Mar 28, 2025
Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: €0.24 (vs €0.075 loss in 2Q 2023)Second quarter 2024 results: EPS: €0.24 (up from €0.075 loss in 2Q 2023). Revenue: €156.8m (up 20% from 2Q 2023). Net income: €9.70m (up €15.3m from 2Q 2023). Profit margin: 6.2% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Revenue is expected to decline by 6.2% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
공시 • May 23Biotest Aktiengesellschaft announces Annual dividend, payable on July 07, 2025Biotest Aktiengesellschaft announced Annual dividend of EUR 0.0400 per share payable on July 07, 2025, ex-date on July 03, 2025 and record date on July 04, 2025.
공시 • May 22Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025Biotest Aktiengesellschaft, Annual General Meeting, Jul 02, 2025, at 10:30 W. Europe Standard Time.
Reported Earnings • May 14First quarter 2025 earnings released: €0.55 loss per share (vs €0.74 profit in 1Q 2024)First quarter 2025 results: €0.55 loss per share (down from €0.74 profit in 1Q 2024). Revenue: €124.2m (down 42% from 1Q 2024). Net loss: €21.4m (down 173% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
공시 • Apr 02Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million.Grifols Biotest Holdings GmbH, proposed to acquire remaining 28.31% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from shareholders for approximately €340 million on March 31, 2025. The Management Board and the Supervisory Board will carefully review the offer document for the public delisting acquisition offer and issue a joint reasoned statement in accordance with Section 27 of the German Securities Acquisition and Takeover Act. The delisting agreement contains provisions that Grifols, S.A. intends to support Biotest AG in an economically reasonable manner. After the revocation of the stock exchange admission becomes effective, the shares of Biotest AG will no longer be admitted to trading on a domestic regulated market or a comparable market abroad. According to the provisions of the delisting agreement, Grifols Biotest Holdings GmbH, a 100% subsidiary of Grifols, S.A., will make an unconditional public delisting acquisition offer to the shareholders of Biotest AG to acquire all ordinary and preference shares of Biotest AG that are not already held by Grifols Biotest Holdings GmbH, in exchange for a cash consideration of €43.00 per Biotest ordinary share and €30.00 per Biotest preference share, subject to adjustments due to legal provisions. The terms and conditions of the delisting offer will be communicated in the offer document ("Offer Document") to be prepared by Grifols and to be examined by the German federal financial supervisory. Banco Santander, S.A. acted as a financial advisor to Biotest Aktiengesellschaft.
Reported Earnings • Apr 01Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: €0.66 (down from €3.21 in FY 2023). Revenue: €726.2m (up 6.1% from FY 2023). Net income: €26.4m (down 79% from FY 2023). Profit margin: 3.6% (down from 19% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
공시 • Mar 18+ 1 more updateBiotest Aktiengesellschaft to Report Q3, 2025 Results on Nov 10, 2025Biotest Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 10, 2025
공시 • Mar 07Martin Möller to Leave as Chief Financial Officer of Biotest AG on 15 March 2025The Board of Management of Biotest AG announced that Chief Financial Officer Martin Möller will terminate his position as CFO as planned at the end of his contract expires on 15 March 2025. The Supervisory Board has already initiated the search for a suitable successor and aims to fill the position in the near future. Martin Möller will continue to support Biotest AG in an advisory capacity beyond the end of his contract.
공시 • Jan 09Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)Biotest AG announced that the Biologics License Application (BLA) for Biotest’s Fibrinogen has been submitted to the US Food and Drug Administration. Fibrinogen is the second product developed and manufactured by Biotest in Dreieich, Germany, for which a BLA has been submitted to the FDA. The new application covers both supplementation in patients with acquired fibrinogen deficiency and treatment and prophylaxis of acute bleeding episodes in all patients with congenital fibrinogen deficiency. The application is now under evaluation by the FDA, with a decision anticipated by the end of 2025. This submission follows Biotest’s earlier application for marketing authorization in selected European markets filed in October 2024. In many regions of the world, the use of cryoprecipitate or fresh frozen plasma as a fibrinogen substitute is the standard of care for the management of major surgical bleeding. However, these treatments contain not only fibrinogen, but also additional proteins and components that may exhibit undesired effects for the patient. In addition, they are not subject to the same rigorous pathogen safety protocols as Fibrinogen. Fibrinogen also offers the significant advantages of being readily available and allowing for faster administration, ensuring timely and targeted treatment.
Reported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: €0.25 loss per share. Revenue: €150.7m (down 40% from 3Q 2023). Net loss: €9.30m (down 108% from profit in 3Q 2023). Revenue is forecast to grow 6.0% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
공시 • Nov 15Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025Biotest Aktiengesellschaft announced that they will report fiscal year 2024 results on Mar 28, 2025
Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: €0.24 (vs €0.075 loss in 2Q 2023)Second quarter 2024 results: EPS: €0.24 (up from €0.075 loss in 2Q 2023). Revenue: €156.8m (up 20% from 2Q 2023). Net income: €9.70m (up €15.3m from 2Q 2023). Profit margin: 6.2% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Revenue is expected to decline by 6.2% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
공시 • Jul 29Biotest Aktiengesellschaft to Report Q2, 2024 Results on Aug 06, 2024Biotest Aktiengesellschaft announced that they will report Q2, 2024 results on Aug 06, 2024
공시 • Jun 18Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary ImmunodeficienciesGrifols announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration (FDA) for Yimmugo®, an innovative intravenous immunoglobulin (Ig) therapeutic, to treat primary immunodeficiencies (PID). Yimmugo, developed by Biotest, adds to Grifols’ strong franchise of industry-leading intravenous and subcutaneous Ig treatments at a time of growing demand for plasma-derived medicines to treat immunodeficiencies, in which a part of the body’s immune system is missing or does not function properly, and other medical conditions. The first U.S.-approved medicine in Biotest’s portfolio, Yimmugo is produced using a state-of-the-art process at Biotest’s new FDA-certified “Next Level” production facility in Dreieich, Germany, which is already approved for production and marketing in Europe. The launch of Yimmugo in the U.S. in the second part of 2024 follows its successful introduction in Europe at the end of 2022 and is poised to add to Grifols' future revenue growth and profitability. Yimmugo is the first of a threesome of Biotest plasma proteins on the horizon destined for markets including the U.S. The other two, both in late-stage development, are a fibrinogen concentrate (FC) to treat acquired fibrinogen deficiency – it would be the first FC approved for this indication in the U.S. – and trimodulin, a polyvalent Ig to treat community-acquired pneumonia (CAP) or severe community-acquired pneumonia (sCAP). The strategic acquisition of Biotest and the integration of its specialized resources has significantly accelerated Grifols innovation, deepened its product pipeline and furthered its industry leadership. Yimmugo is a newly developed polyvalent immunoglobulin G preparation from human blood plasma for intravenous administration (IVIg). The sugar-free ready-to-use solution is approved in the US for substitution therapy in primary antibody deficiency syndromes. Yimmugo is the first approved product from the new Biotest Next Level production facility. The modern production process stands for the highest product quality and an extremely responsible use of resources. Important Safety Information: Thrombosis may occur with immune globulin intravenous (IGIV) products, including YIMMUGO. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer YIMMUGO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Reported Earnings • May 07First quarter 2024 earnings released: EPS: €0.74 (vs €0.53 loss in 1Q 2023)First quarter 2024 results: EPS: €0.74 (up from €0.53 loss in 1Q 2023). Revenue: €215.2m (up 84% from 1Q 2023). Net income: €29.5m (up €49.9m from 1Q 2023). Profit margin: 14% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is expected to decline by 4.8% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Upcoming Dividend • May 01Upcoming dividend of €0.08 per shareEligible shareholders must have bought the stock before 08 May 2024. Payment date: 13 May 2024. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.8%).
New Risk • Mar 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 53% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.9x net interest cover). Earnings are forecast to decline by an average of 53% per year for the foreseeable future.
Reported Earnings • Mar 30Full year 2023 earnings: Revenues exceed analyst expectationsFull year 2023 results: Revenue: €684.6m (up 33% from FY 2022). Net income: €127.0m (up €158.7m from FY 2022). Profit margin: 19% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 21%. Revenue is forecast to grow 2.0% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Germany.
공시 • Mar 29Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024, at 10:30 Central European Standard Time. Location: Alte Oper Frankfurt, Mozart Saal, Opernplatz, Franfurt Am Main Germany Agenda: To consider the adopted annual financial statements of Biotest AG and the approved consolidated financial statements as at 31 December 2023; to consider the Resolution on the discharge of the members of the Management Board for the financial year 2023; to consider Resolution on the discharge of the members of the Supervisory Board for the financial year 2023; to consider the Election of the auditor for the financial year 2024; and to consider the other business matters.
공시 • Jan 23+ 2 more updatesBiotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024Biotest Aktiengesellschaft announced that they will report first half, 2024 results on Jul 30, 2024
공시 • Nov 03Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024Biotest Aktiengesellschaft announced that they will report fiscal year 2023 results on Mar 28, 2024
Reported Earnings • Nov 02Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: €252.8m (up 135% from 3Q 2022). Net income: €114.4m (up €128.7m from 3Q 2022). Profit margin: 45% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
공시 • Oct 07Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023Biotest Aktiengesellschaft raised earnings guidance for the year 2023. Biotest AG had forecasted in April 2023 an EBIT that may possibly exceed EUR 100 million. Based on current information, the Executive Board expects EBIT for fiscal 2023 to be in the order of EUR 130 - 170 million. The Executive Board continues to aim for a mid-single-digit percentage increase in revenue for the 2023 financial year compared to 2022, excluding revenue from the technology transfer and licensing agreement.
공시 • Oct 06Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024Biotest AG at its meeting held on October 5, 2023 appointed Mr. Peter Janssen (57) as Chairman of the Management Board of Biotest AG with effect from 1 January 2024. He will take over the chairmanship of the Board of Management from Dr Michael Ramroth (62), who held this position for three and a half years and is retiring as planned for reasons of age. Peter Janssen has been a member of the Management Board of Biotest AG since 2022 and heads the Commercial and Industrial Operations divisions. Previously, he was Executive VP of Prothya Netherlands and CEO of Prothya Belgium. Mr. Janssen also worked for Pfizer for 14 years and for its animal health spin-off Zoetis for 5 years. Peter Janssen started his career as an assistant professor at the University of Leuven in Belgium, was a reserve officer in the Belgian Air Force and worked in the semiconductor division of the industrial gas company Air Products in Pennsylvania, USA. He holds a Master of Science (Dipl. Ing.) in Electromechanics, a Master in Business Administration and a Management Diploma from INSEAD in France. In addition to Peter Janssen as Chairman of the Management Board, the Management Board of Biotest AG will continue to include Ainhoa Mendizabal Zubiaga as CFO and Dr. Jörg Schüttrumpf as CSO.
New Risk • Sep 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€146m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company.
공시 • Sep 13Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with TrimodulinBiotest announced that the first patient with sCAP has been treated in the phase III ESsCAPE trial in an intensive care unit. This multinational phase III clinical trial is expected to enrol approximately 590 adult patients with severe Community Acquired Pneumonia (sCAP). The ESsCAPE trial will be conducted in up to 20 countries worldwide and patients will receive either trimodulin or placebo as add-on therapy to standard of care. Severe CAP is a life-threatening condition. Patients must be admitted to an intensive care unit (ICU) and often receive oxygen through invasive mechanical ventilation (IMV). These patients often develop additional critical illnesses such as sepsis, septic shock, and multiple organ dysfunction or failure. Despite existing treatment options, mortality in these patients remains high. The clinical concept of this prospective, double-blind, placebo-controlled phase III trial, was developed based on the promising results of the previous phase II clinical trial (CIGMA) in 160 sCAP patients requiring IMV. In the CIGMA trial a subgroup of patients with evidence of severe inflammation showed an encouraging reduction in the mortality rate when treated with trimodulin. Biotest's development product trimodulin is a globally unique, innovative polyvalent IgM, IgA, IgG antibody composition, purified from human plasma. In addition to clinical development for sCAP, trimodulin is also currently in development for the treatment of COVID-19. Biotest's development products trimodulin is an innovative polyvalent antibody composition, purified from human Plasma. In comparison to standard IgG preparations (IVIG), trimodulin contains relevant amounts of IgM and IgA in addition to IgG. Trimodulin is currently in clinical development for the treatment of patients with severe community-acquired pneumonia (sCAP) and for patients with moderate or severe COVID-19. Research so far has shown that trimodulin could intervene with a number of mechanisms involved in pathological processes that would otherwise lead to respiratory failure, sepsis, multi-organ failure and finally to death of the patient. Due to the large variety of polyvalent antibodies present in trimodulin, the impaired immune system is supported in various ways. The antibodies bind to various types of pathogens including viruses and bacteria as well as their toxins and support their clearance by the immune system. Particularly the IgM component in trimodulin can reduce dysregulated immune responses, preventing the immune system to attack host tissues, in this case, the lung. In this way, trimodulin may prevent progression of disease, including the need for invasive mechanical ventilation and other intensive care procedures, and finally death. Severe community acquired pneumonia (sCAP) is usually defined as pneumonia acquired outside the hospital that requires intensive medical care. mortality of sCAP patients admitted to the intensive care unit is high and has not improved much in recent years.
공시 • Sep 08Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin YimmugoBiotest AG announced that the Biologics License Application (BLA) for the polyspecific immunoglobulin preparation Yimmugo (IgG Next Generation) has been accepted for review by the U.S. Food and Drug Administration (FDA) after the 60-day validation phase. With this filing notification the marketing authorization application will enter the next phase, in which the application dossier will be subjected to an in-depth substantive review. The marketing authorization application covers the indication primary immunodeficiencies (PID). After receiving approval, Biotest plans to expand the indication to include chronic primary immune thrombocytopenia (ITP). The FDA's decision on the marketing authorization application of Yimmugo is expected on June 29, 2024. Biotest's new immunoglobulin is manufactured in an innovative production process and is the main product of the new Biotest Next Level production facility. The new production facility, which uses technologies, represents Biotest's increased commitment to the global immunoglobulin market.
Reported Earnings • Aug 13Second quarter 2023 earnings released: EPS: €0.55 (vs €0.39 loss in 2Q 2022)Second quarter 2023 results: EPS: €0.55 (up from €0.39 loss in 2Q 2022). Revenue: €158.0m (up 15% from 2Q 2022). Net income: €22.2m (up €37.2m from 2Q 2022). Profit margin: 14% (up from net loss in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Reported Earnings • May 10First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €117.2m (up 1.1% from 1Q 2022). Net loss: €20.4m (loss widened 316% from 1Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Mar 24Full year 2022 earnings: Revenues miss analyst expectationsFull year 2022 results: Revenue: €516.1m (flat on FY 2021). Net loss: €31.7m (loss narrowed 50% from FY 2021). Revenue missed analyst estimates by 2.2%. Revenue is forecast to grow 9.5% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
Buying Opportunity • Mar 13Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.0%. The fair value is estimated to be €40.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.5% over the last 3 years. Earnings per share has declined by 56%. Revenue is forecast to grow by 21% in 2 years. Earnings is forecast to grow by 86% in the next 2 years.
공시 • Feb 11Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023Biotest AG appointed Ms. Ainhoa Mendizabal (50) to the company's Management Board as Chief Financial Officer (CFO) with effect from 15 February 2023. When Dr. Michael Ramroth was appointed Chief Executive Officer (CEO) on 1 May 2019, he initially continued to perform the duties of Chief Financial Officer in addition to his other duties. In view of the constantly growing reporting requirements, the company has now filled the position of Chief Financial Officer with Ms Mendizabal. As 'Chief Financial Officer', Ms. Mendizabal will be responsible within the Biotest Group for the areas of finance, including the treasury and tax departments, controlling, investor relations and insurance. Ms Mendizabal has worked for several years in an international consulting firm in the area of CFO Services and Enterprise Applications. From there she moved to Talecris Biotherapeutics GmbH before Talecris was acquired by Grifols S.A. Since then, Ms Mendizabal has held various executive and managerial roles in the Grifols Group in Germany and in Europe. Ms. Mendizabal holds a dual Master of Business Administration (Business Administration) in Spain and in Germany.
공시 • Dec 20+ 2 more updatesBiotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023Biotest Aktiengesellschaft announced that they will report fiscal year 2022 results at 12:00 PM, Central European Standard Time on Mar 23, 2023
Reported Earnings • Nov 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €107.7m (down 5.2% from 3Q 2021). Net loss: €14.3m (loss widened 42% from 3Q 2021). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Germany.
Breakeven Date Change • Sep 15No longer forecast to breakevenThe 2 analysts covering Biotest no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €9.06m in 2023. New consensus forecast suggests the company will make a loss of €3.00m in 2024.
Reported Earnings • Aug 14Second quarter 2022 earnings released: €0.39 loss per share (vs €0.11 loss in 2Q 2021)Second quarter 2022 results: €0.39 loss per share (down from €0.11 loss in 2Q 2021). Revenue: €137.2m (flat on 2Q 2021). Net loss: €15.0m (loss widened 266% from 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 06First quarter 2022 earnings: Revenues in line with analyst expectationsFirst quarter 2022 results: Revenue: €115.9m (down 3.4% from 1Q 2021). Net loss: €4.90m (loss narrowed 65% from 1Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 2.5%, compared to a 28% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • Apr 29Upcoming dividend of €0.04 per shareEligible shareholders must have bought the stock before 06 May 2022. Payment date: 10 May 2022. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (4.0%). Lower than average of industry peers (1.4%).
Major Estimate Revision • Apr 04Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €0.06 to €0.08. Revenue forecast steady at €559.5m. Net income forecast to grow 60% next year vs 24% growth forecast for Biotechs industry in Germany. Consensus price target of €36.58 unchanged from last update. Share price was steady at €34.70 over the past week.
Major Estimate Revision • Dec 11Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -€0.53 to -€1.06 per share. Revenue forecast unchanged at €511.5m. Biotechs industry in Germany expected to see average net income growth of 3.4% next year. Consensus price target broadly unchanged at €39.13. Share price fell 2.8% to €38.10 over the past week.
Price Target Changed • Nov 13Price target increased to €38.93Up from €36.23, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of €39.00. The company is forecast to post a net loss per share of €0.54 next year compared to a net loss per share of €0.80 last year.
Reported Earnings • Nov 12Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: €113.6m (up 6.4% from 3Q 2020). Net loss: €10.1m (loss narrowed 33% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 13Second quarter 2021 earnings released: €0.11 loss per share (vs €0.16 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses and improved control over expenses, although revenues were flat. Second quarter 2021 results: Revenue: €137.8m (flat on 2Q 2020). Net loss: €4.10m (loss narrowed 29% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 12First quarter 2021 earnings released: €0.37 loss per share (vs €0.28 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: €120.0m (up 23% from 1Q 2020). Net loss: €14.1m (loss widened 31% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • May 05Upcoming dividend of €0.04 per shareEligible shareholders must have bought the stock before 12 May 2021. Payment date: 17 May 2021. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (0.5%).
Reported Earnings • Apr 04Full year 2020 earnings released: €0.80 loss per share (vs €0.13 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €484.2m (up 16% from FY 2019). Net loss: €31.8m (loss widened €26.7m from FY 2019). Products in clinical trials Phase I: 1 Phase II: 1 Phase III: 5 Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • Apr 02Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from €497.9m to €508.0m. Forecast EPS reduced from -€0.52 to -€0.60 per share. Biotechs industry in Germany expected to see average net income growth of 7.3% next year. Consensus price target up from €31.20 to €35.60. Share price was steady at €29.90 over the past week.
Is New 90 Day High Low • Feb 12New 90-day high: €28.80The company is up 10.0% from its price of €26.10 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period.
Is New 90 Day High Low • Jan 14New 90-day high: €28.50The company is up 4.0% from its price of €27.40 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also up 4.0% over the same period.
Reported Earnings • Nov 13Third quarter 2020 earnings released: €0.39 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: €106.8m (up 7.0% from 3Q 2019). Net loss: €15.1m (loss widened 208% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
Major Estimate Revision • Sep 25Analysts update estimatesThe company's losses in 2020 are expected to worsen with analysts lowering their consensus EPS forecasts from -€0.64 to -€0.72. Revenue estimate was approximately flat at €461.0m. The Biotechs industry in Germany is expected to see an average net income growth of 9.9% next year. The consensus price target increased from €24.10 to €31.20. Share price is down by 2.0% to €24.80 over the past week.